CD274 and neoplasm: Previous studies have developed various biomarkers to differentiate patients who could benefit from ICI treatment, such as PD‐L1 immunohistochemistry (IHC) of tumor tissue, tumor mutational burden (TMB), tumor‐infiltrating lymphocytes (TILs), and microsatellite instability (MSI) status.10, 11, 12, 13